Chrysalis

AeroVironment, Inc. to Acquire Tomahawk Robotics

Retrieved on: 
Tuesday, August 22, 2023

The two companies entered into a definitive agreement under which AeroVironment will acquire 100% of Tomahawk Robotics equity for a total purchase price of $120 million to be paid in a mix of cash and stock.

Key Points: 
  • The two companies entered into a definitive agreement under which AeroVironment will acquire 100% of Tomahawk Robotics equity for a total purchase price of $120 million to be paid in a mix of cash and stock.
  • Tomahawk Robotics will become part of the small UAS (SUAS) business unit within AeroVironment’s Unmanned Systems segment.
  • “We will support all existing Tomahawk Robotics customers and their products will remain platform agnostic to the market and within the industry.
  • “Tomahawk Robotics’ solutions will accelerate our adoption and implementation of AI and autonomy into AeroVironment platforms,” continued Stevenson.

Tomahawk Robotics Integrates AeroVironment UAS Into Kinesis Ecosystem

Retrieved on: 
Wednesday, March 9, 2022

MELBOURNE, Fla., March 9, 2022 /PRNewswire/ -- Tomahawk Robotics , the leading innovator of common control solutions, has integrated the AeroVironment RQ-11 Ravenunmanned aircraft system (UAS) into the Kinesis Ecosystem with AeroVironment's Crysalison Tomahawk Robotics' KxM edge processor.

Key Points: 
  • MELBOURNE, Fla., March 9, 2022 /PRNewswire/ -- Tomahawk Robotics , the leading innovator of common control solutions, has integrated the AeroVironment RQ-11 Ravenunmanned aircraft system (UAS) into the Kinesis Ecosystem with AeroVironment's Crysalison Tomahawk Robotics' KxM edge processor.
  • AeroVironment's RQ-20 Puma is the next UAS slated for Kinesis integration via Crysalis.
  • Kinesis users can look forward to this capability in the next Kinesis release.
  • The collaboration between AeroVironment and Tomahawk Robotics extends the variety of robotic platforms that Marines are able to control via the Radio Agile Integrated Device (RAID) Program.

Pernod Ricard: Combined Shareholders’ Meeting of 10 November 2021

Retrieved on: 
Wednesday, November 10, 2021

On this day, the shareholders of Pernod Ricard (Paris:RI) have held their Combined Shareholders Meeting chaired by Mr. Alexandre Ricard, Chairman & CEO, in order to approve, in particular, the consolidated and company financial statements of Pernod Ricard SA for the year ended 30 June 2021.

Key Points: 
  • On this day, the shareholders of Pernod Ricard (Paris:RI) have held their Combined Shareholders Meeting chaired by Mr. Alexandre Ricard, Chairman & CEO, in order to approve, in particular, the consolidated and company financial statements of Pernod Ricard SA for the year ended 30 June 2021.
  • A summary table of the Board Committees, as composed after todays General Meeting, is also attached hereto.
  • He joined Pernod Ricard in 2008 as an internal auditor in the Audit and Business Development Department at the Headquarters.
  • He has been the permanent representative of Socit Paul Ricard (Director of Pernod Ricard) since 29 August 2012.

Chrysalis Raises $1.15M To Support Employment Solutions For People Experiencing Homelessness At Second Chrysalis Night In Virtual Gala

Retrieved on: 
Friday, May 14, 2021

b'LOS ANGELES, May 14, 2021 /PRNewswire/ -- Chrysalis , a Southern California-based nonprofit dedicated to creating a pathway to self-sufficiency for people experiencing homelessnessand economic barriers to the workforce, celebrated its second Chrysalis Night In on Thursday, May 13.

Key Points: 
  • b'LOS ANGELES, May 14, 2021 /PRNewswire/ -- Chrysalis , a Southern California-based nonprofit dedicated to creating a pathway to self-sufficiency for people experiencing homelessnessand economic barriers to the workforce, celebrated its second Chrysalis Night In on Thursday, May 13.
  • The organization is thrilled to announce that as a result of generous donations, sponsorships, and ticket sales it raised $1.15M in funding, more than doubling the funds raised from last year\'s inaugural event.
  • "Over the past year, we have welcomed more than 3,000 new clients virtually.
  • "\nTo learn more about Chrysalis, visit ChangeLives.org .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/chrysalis-raises-1-15m-to-suppor...\n'

While Others Cut Back, National Health Foundation Partners with Chrysalis to Increase Job Opportunities

Retrieved on: 
Tuesday, January 26, 2021

"Hiring opportunities with the National Health Foundation provide a key that will unlock not just a job that will keep them financially secure during this unsettling time, but also open the door to a new path for their lives."

Key Points: 
  • "Hiring opportunities with the National Health Foundation provide a key that will unlock not just a job that will keep them financially secure during this unsettling time, but also open the door to a new path for their lives."
  • Throughout the pandemic, 13 temporary employees have transitioned into full-time roles at National Health Foundation as Guest Service Associates.
  • "Chrysalis is truly a blessing to me because without them I would have never been connected to National Health Foundation.
  • I want to help others the same way Chrysalis and NHF helped me," shares Chrysalis client and NHF staff member Dwona Beroit.

Two Wall Street Pros named to lead Chrysalis Holdings LLC To Drive Growth In Its FinTech Companies which includes Leading Veteran Mortgage Lender, NewDay USA

Retrieved on: 
Tuesday, December 15, 2020

"David has been an advisor to Chrysalis and NewDay USA since 2009, providing guidance about financial markets and capitalization strategy," said Robert Posner, CEO of NewDay USA and CEO of Chrysalis Holdings.

Key Points: 
  • "David has been an advisor to Chrysalis and NewDay USA since 2009, providing guidance about financial markets and capitalization strategy," said Robert Posner, CEO of NewDay USA and CEO of Chrysalis Holdings.
  • "In his role as Chairman of Chrysalis, David will provide significant value and direction for our future strategic growth."
  • Olson, a Wall Street veteran, is the founder and CEO of Wind River Capital LLC, a boutique investment bank.
  • Current key holdings include NewDay Financial LLC, Chrysalis Analytics LLC and NewDay India Software Development Private Ltd.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/two-wall-street-pros-named-to-le...

Fine-Grained Authorization Leader from Axiomatics to Speak at TechVision's Chrysalis Conference 2019

Retrieved on: 
Wednesday, October 30, 2019

CHICAGO, Oct. 30, 2019 /PRNewswire-PRWeb/ -- Axiomatics , the leader in externalized, fine-grained dynamic authorization, today announced that Gerry Gebel, vice president of business development, will speak at the inaugural TechVision Chrysalis Conference 2019, November 11-14 at the Manchester Grand Hyatt in San Diego.

Key Points: 
  • CHICAGO, Oct. 30, 2019 /PRNewswire-PRWeb/ -- Axiomatics , the leader in externalized, fine-grained dynamic authorization, today announced that Gerry Gebel, vice president of business development, will speak at the inaugural TechVision Chrysalis Conference 2019, November 11-14 at the Manchester Grand Hyatt in San Diego.
  • The TechVision Chrysalis Conference 2019 was designed for candid and user-centric conversations surrounding the challenges that IT professionals face.
  • The conference includes an attendee-driven agenda, high-profile expert speakers, in-depth content and an independent point of view.
  • Attendees of the TechVision Chrysalis Conference 2019 includes enterprise-focused industry, technology and business experts dedicated to improving the constantly evolving, enterprise security industry.

Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million

Retrieved on: 
Tuesday, August 27, 2019

Under this contract, Chrysalis will receive initial funding of $10,074,093 to support preclinical development to assess efficacy of TP508.

Key Points: 
  • Under this contract, Chrysalis will receive initial funding of $10,074,093 to support preclinical development to assess efficacy of TP508.
  • The contract includes subsequent options that may be exercised by BARDA in its sole discretion upon achievement of certain milestones.
  • If the options are exercised in full, Chrysalis could receive up to an additional $95,163,711 over the next 5 years.
  • This base award of just over $10 million brings the total of Chrysalis non-dilutive funding from federal sources (National Institutes of Health (NIAID and NCI) and BARDA) to over $24 million.